In a prospective study with 200 hyperprolactinemia patients (52% microprolactinoma and 35% macroprolactinoma), cabergoline was phased out among patients who met the following criteria: (i) normalization of serum prolactin; (ii) absent tumor or reduction in tumor volume by at least 50% upon imaging; and (iii) no invasion of cavernous sinus and tumor located at least 5 mm from the optic chiasm. This evidence concerns the gene PRL and hyperprolactinemia.